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A B S T R A C T
The lectin DLasiL was isolated from seeds of the Dioclea lasiocarpa collected from the northeast coast of Brazil
and characterized for the ﬁrst time by mass spectrometry, DNA sequencing, inductively coupled plasma-mass
spectrometry, electron paramagnetic resonance, and ﬂuorescence spectroscopy. The structure of DLasiL lectin
obtained by homology modelling suggested strong conservation of the dinuclear Ca/Mn and sugar-binding sites,
and dependence of the solvent accessibility of tryptophan-88 on the oligomerisation state of the protein. DLasiL
showed highly potent (low nanomolar) antiproliferative activity against several human carcinoma cell lines
including A2780 (ovarian), A549 (lung), MCF-7 (breast) and PC3 (prostate), and was as, or more, potent than the
lectins ConBr (Canavalia brasiliensis), ConM (Canavalia maritima) and DSclerL (Dioclea sclerocarpa) against A2780
and PC3 cells. Interestingly, DLasiL lectin caused a G2/M arrest in A2780 cells after 24 h exposure, activating
caspase 9 and delaying the on-set of apoptosis. Confocal microscopy showed that ﬂuorescently-labelled DLasiL
localized around the nuclei of A2780 cells at lectin doses of 0.5–2× IC50 and gave rise to enlarged nuclei and
spreading of the cells at high doses. These data reveal the interesting antiproliferative activity of DLasiL lectin,
and suggest that further investigations to explore the potential of DLasiL as a new anticancer agent are war-
ranted.
1. Introduction
Cancer is the leading cause of morbidity and mortality around the
world, with approximately 14 million new cases and 8.2 million cancer
related deaths worldwide in 2012 [1]. Furthermore, the number of new
cases in developed countries is expected to rise up to 70% in the next
decades [1], due to population ageing and growth [2]. Hence there is a
need for discovery of new anticancer drugs, especially those with novel
mechanisms of action that can combat resistance.
There is increasing interest in the role of glycans on the surface of
tumour cells in relation to tumour cell division, migration (metastasis)
and recognition by the immune system (lymphocytes) [3]. Cancer cells
show many altered glycosylation patterns including those of cell surface
biomolecules, such as glycolipids and glycoproteins, which may aﬀect a
range of processes including the transcription of genes, traﬃcking, or
retention of biomolecules [4]. These aberrant changes provide a basis
for the discovery of biomarkers and therapeutic agents capable of tar-
geting cells by recognizing particular glycosylation patterns.
Lectins are carbohydrate-binding proteins that fulﬁl multiple bio-
logical roles. They are ubiquitously distributed in nature, being found in
vertebrates, invertebrates, bacteria, viruses and plants. These proteins
bind speciﬁcally to certain sugars, glycoproteins and glycolipids, and
have a variety of functions in mammals, for example roles on cell sur-
faces and in the immune system. In general, plant lectins have been
used in cell biology and immunology as diagnostics [5] and as im-
munomodulatory agents [6], as well as for therapeutic purposes [4].
Lectins have potential as oral drugs since they are often resistant to
digestion. Importantly they survive passage through the gut, bind to
gastrointestinal cells, enter the circulation intact, and maintain their
biological activity [7]. Plant lectins from nuts and seeds are the most
widely studied, especially Concanavalin A (ConA), a homo-tetramer
(4 × 26.5 kDa) with Mn(II) and Ca(II) ions bound at 4 binuclear
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binding sites per tetramer, and with speciﬁcity for mannosyl and gly-
cosyl sugars [8,9]. Interestingly, despite the high similarity amongst
plant lectins, many have shown remarkably distinct biological proﬁles,
with a vast range of biological activities which include anti-in-
ﬂammatory [10], antidepressive [11], anticonceptive [12] and vaso-
dilatory activities [8]. A few lectins have been recently identiﬁed as
promising antitumour agents, for example ConA and the lectin ML-I
from mistletoe are in pre-clinical and clinical trials for human liver
cancer and malignant melanoma [13,14].
Lectins appear to inhibit tumour growth in vitro and in vivo by
preferential binding to cell membranes of cancer cells or to their re-
ceptors [7,15,16]. Nevertheless, this binding leads to diﬀerent cellular
eﬀects that depend on the lectin, such as the activation of protein ki-
nases, or alteration of the production of interleukins leading to im-
munological responses [7]. Additionally, plant lectins also have a role
in triggering diﬀerent cell death pathways, including apoptosis, ne-
crosis and/or autophagy [3,7,14,17–19]. For example, ML-I (Mistletoe
lectin I from Viscum album) and Ricin A (from Ricinus communis) bind to
ribosomes and inhibit protein synthesis in vitro, while RBA (Rice bran
agglutinin) or WGA (Wheat germ agglutinin) induce G2/M cell cycle
arrest and downstream apoptosis [7]. BFL (from Bauhinia forﬁcata) has
potent anticancer activity towards MCF-7 cancer cells, causing DNA
fragmentation and cell cycle arrest at the G2/M phase, along with in-
hibition of caspase 9 leading to primary and secondary necrosis [20].
However, determination of their mechanism of action is not always
straightforward. Another similar lectin BG2 (from Bauhinia variegata)
inhibits cell proliferation of MCF-7 breast cancer cells and HepG2 he-
patomas, displaying IC50 values of 0.18 and 1.4 μM, respectively, but its
cellular behaviour and mechanism of action have not yet been eluci-
dated [21].
Recently, we isolated DLasiL from the seed pods of Dioclea lasio-
carpa, a ﬂowering plant found in Northeastern Brazil. DLasiL is a ConA-
like seed lectin with high binding speciﬁcity for glucose/mannose and
shows contractile activity on isolated rat aorta with possible involve-
ment of endothelium-derived factors [22]. However, this lectin has not
been thoroughly characterized, nor its detailed biological properties
explored. Here we investigate the potential of DLasiL as an anticancer
agent by studying its antiproliferative activity, cell cycle eﬀects and cell
death processes in A2780 ovarian, A549 lung, PC3 prostate and MCF-7
breast human cancer cell lines.
2. Material and methods
2.1. Lectin puriﬁcation
The lectins were extracted from seeds of Canavalia brasiliensis,
Canavalia maritima, Dioclea lasiocarpa and Dioclea sclerocarpa. The
protein extractions were performed on ﬁne seed powders, prepared for
each species, at ambient temperature by stirring for 4 h in 0.1 M Tris-
HCl buﬀer pH 7.4 with 0.15 M NaCl. The crude extract was then ﬁltered
and centrifuged at 10,000 ×g for 30 min. The pellet was discarded and
the supernatant was transferred to a Sephadex G-50 column previously
equilibrated with 0.1 M Tris-HCl buﬀer pH 7.4 with 0.15 M NaCl, 5 mM
CaCl2, and 5 mM MnCl2. The retained fraction corresponding to the
puriﬁed protein was eluted with 0.2 M glucose containing 0.15 M NaCl,
and subsequently dialyzed against water, lyophilized, and stored at
ambient temperature. Protein concentration and purity were analyzed
by the Bradford method, electronic absorption spectroscopy and SDS-
PAGE [23,24].
2.2. Protein digestion and tandem mass spectrometry analysis
After a 12% SDS-PAGE, DLasiL bands were excised and bleached in
a solution of 50 mM ammonium bicarbonate in 50% v/v acetonitrile.
The bands were then dehydrated in 100% acetonitrile and dried in a
Speedvac (LabConco). The gel was rehydrated overnight at 310 K with
a solution of 50 mM ammonium bicarbonate, pH 8.0, containing trypsin
(Promega; 1:50 w/w enzyme:substrate ratio). The peptides were ex-
tracted from the gel and concentrated, followed by injection into a
NanoAcquity system (Waters, Corp., Milford, USA) connected to the
electrospray source of a mass spectrometer (SYNAPT HDMS system;
Waters Corp., Milford, CT, USA). The sample was applied to a C18
chromatography column (75 μm× 100 mm) and eluted with a 10–85%
acetonitrile gradient containing 0.1% formic acid. The mass spectro-
meter was operated in positive mode with 363 K source temperature
and 3.0 kV capillary voltage. The LC-MS/MS experiment was performed
with the DDA (data dependent analysis) function, which selects doubly-
or triply-charged precursor ions, for fragmentation by collision-induced
dissociation (CID). The data were processed and analyzed with
ProteinLynx v2.4 (Waters) using the peptide fragmentation pattern as
search parameter. Some peptide sequences were determined by manual
de novo sequencing. Primary structure alignments were made with
ESPript 2.2 [25].
2.3. DLasiL gene cloning and sequencing
Genomic DNA was isolated from young leaves of Dioclea lasiocarpa
using a method based on the detergent cetyltrimethylammonium bro-
mide (CTAB). The DLasiL gene was ampliﬁed by PCR using speciﬁc
primers, D_forward (TCA AA AAA ATC TCT GAT G) and D_reverse (TCA
GAC GAC GGA TGC AAT), designed based on the N- and C-terminal
sequences of Diocleinae lectins. The ampliﬁed fragment was puriﬁed
using the kitPureLink™ QuickGel Extration (Invitrogen™/Life
Technologies) and cloned into pGEM-T Easy Vector (Promega, USA).
Escherichia coli DH5α cells (Novagen) were transformed by electro-
poration with an Eppendorf 2510 electroporator, following the manu-
facturer's instructions. The construct DlasiL:pGEM-T was sequenced
with an MegaBASE 1000 DNA sequencer (GE-Healthcare). The reads
were analyzed by the Phred-Phrap-Consed package.
2.4. Electron paramagnetic resonance spectroscopy
Electron paramagnetic resonance spectroscopy (EPR) was used to
conﬁrm the presence of Mn(II) in the leguminous lectins ConBr, ConM,
DLasiL and DSclerL. Solutions containing ca. 0.4 mM of proteins were
made up from the lyophilized powders in Milli-Q water; no buﬀer was
used.
All EPR spectra were recorded on aqueous samples (150 μL) on a
Bruker EMX (X-band) spectrometer at ambient temperature (ca. 291 K)
in a cylindrical Tm110 mode cavity (Bruker 4103TM). Spectrosil quartz
tubes with inner diameter of 1.0 and 1.2 mm were used, sealed with T-
Blu Tac®, and placed inside a larger quartz tube (O.D. 2.0 mm). The
EPR parameters were: modulation amplitude 10 G, microwave power
0.63 mW, 6.3 × 105 receiver gain, sweep gain 40.96 s with resolution
2048 resolution in X. The spectra were analyzed by the software Bruker
WINEPR.
2.5. Inductively coupled plasma-mass spectrometry
The metal content of puriﬁed ConBr, ConM, DLasiL and DSclerL
lectins was determined by inductively coupled plasma-mass spectro-
metry (ICP-MS) using an Agilent 7500cx instrument with an IAS (in-
tegrated auto sampler). The parameters were: plasma gas ﬂow (argon):
15 L/min, auxiliary gas: 0.9 L/min, forward power 1550 W, ORC (oc-
topole reaction cell) used in helium mode (Tune ﬁle 1), no ORC (Tune
ﬁle 2), internal standard 166Er; no other corrections were used and
sample delivery was 0.3 rps. The lectins were digested by treatment
with 5% v/v of nitric acid for 1 h and diluted with double deionized
water (DDW). The metal isotopes detected were 12Mg, 20Ca, 25Mn, 27Co,
28Ni, 30Zn. Only 12Mg, 20Ca, 25Mn were found in signiﬁcant amounts for
precise quantitation. Standards used in the experiments were purchased
from Sigma Aldrich and freshly prepared for each experiment.
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2.6. Fluorescence spectroscopy
Steady-state ﬂuorescence emission measurements were obtained on
a Jasco FP 6500 (Jasco International Co., Ltd., Tokyo, Japan), equipped
with a 150 W xenon lamp, using a quartz cuvette (volume 500 μL;
pathlength 1 cm). The slit widths on the excitation and emission
monochromators were 5 and 10 nm, respectively. To excite tryptophan
residues of the proteins, the samples were irradiated at 295 nm with
OD295nm≤ 0.05; the emission spectra were recorded between 305 and
450 nm. Titrations of DLasiL solutions with aliquots of quenchers or
ﬂuorophore stocks, such as acrylamide, cesium chloride, and potassium
iodide were carried out. Brieﬂy, the decrease of ﬂuorescence intensity
was observed after serial addition of small aliquots of freshly prepared
stocks of quenchers to a buﬀered solution of DLasiL (in 10 mM phos-
phate-buﬀered saline solution containing 2.7 mM NaCl) in a cuvette,
followed by mixing and incubation for 2 min in the sample compart-
ment in the dark. Sodium thiosulfate (0.2 mM ﬁnal concentration), was
added to the iodide stock solution to avoid formation of triiodide (I3−)
as described elsewhere [26]. Experiments with denatured DLasiL were
performed by pre-treating the protein with 6 M Gdn·HCl at room tem-
perature for 12 h. All the spectra were corrected, subtracted with ap-
propriate blank without DLasiL and experiments were performed in
duplicate at 298 K. Quenching data were analyzed by ﬁtting to the
Stern–Volmer equation [27]:
= +F F 1 K [Q],0 SV
where F0 and F are the ﬂuorescence intensities at the maximum of the
protein emission bands in the absence and presence of the quencher,
respectively, [Q] is the molar quencher concentration and KSV is the
Stern–Volmer quenching constant. The modiﬁed Stern-Volmer equation
was also tested, but did not improve the ﬁt.
2.7. Circular dichroism spectroscopy
Circular dichroism (CD) spectra were obtained on a Jasco J-810
spectropolarimeter (Jasco International Co., Ltd., Tokyo, Japan)
equipped with a Peltier thermostat, using a 1 mm pathlength rectan-
gular quartz cell. A DLasiL concentration of ca. 10 μM was used for
recording CD spectra in the near-UV region (300–250 nm). The thermal
unfolding properties of DLasiL were investigated by recording CD
spectra in the near-UV region at various temperatures. All experiments
were performed in 10 mM sodium phosphate buﬀer at pH 7.4 in the
absence or presence of mannose or glucose to investigate binding and
structural changes.
2.8. Homology modelling
The most suitable template for Dioclea lasiocarpa lectin was identi-
ﬁed using the remote homology recognition server Phyre [28], which
also produces multiple and pairwise sequence alignments. The template
structure with the highest % identity (96%) was pdb 1H9W, for a seed
lectin from Dioclea guianensis [29]. Due to the extremely high similarity
between model and template sequence, the homology model generated
by the Phyre server was used for inspecting tryptophan, metal, and
saccharide environments without further manipulations. The physical
soundness of the model was checked using the WHATIF web interface
(http://swift.cmbi.ru.nl/servers/html/index.html). To explore trypto-
phan environments in the functional biological assembly, pdb 4H55
(containing a monomer in the asymmetric unit) was analyzed using the
pdbePISA server at EBI (http://www.ebi.ac.uk/pdbe/pisa/). This
yielded the desired tetrameric assembly [30] shown in Fig. S6. In ad-
dition, the dimeric structure from pdb 1H9W was also inspected in this
regard.
Structural overlays and comparisons were performed in Swiss pdb
viewer v. 3.7, and structural images were generated either in the latter
program or in MOLMOL v. 2k.1 [31].
2.9. Cell culture
Human ovarian carcinoma (A2780), human Caucasian lung carci-
noma (A549), human prostate carcinoma (PC3) and human breast
carcinoma (MCF-7) were purchased from ECACC (European Collection
of Animal Cell Culture, Salisbury, UK). A2780 and PC3 cells were cul-
tured in Roswell Park Memorial Institute medium (RPMI-1640) while
A549 and MCF-7 were kept in Dulbecco's Modiﬁed Eagle medium
(DMEM). Both cell-culture media were supplemented with 10% v/v of
foetal calf serum, 1% v/v of L-glutamine and 1% v/v penicillin/strep-
tomycin, and cells were grown as single monolayers at 310 K in a hu-
midiﬁed atmosphere containing 5% CO2. The cells were sub-cultured at
regular intervals, the passages were made by trypsinizing the cells when
80–90% of conﬂuence was achieved. For all assays involving lectins,
medium with only 1% foetal calf serum was used to avoid lectin de-
activation by non-speciﬁc protein binding.
2.10. Cell viability assays
The antiproliferative activity of the lectins (ConBr, ConM, DLasiL
and DSclerL) towards A2780, A549, PC3 and MCF-7 cancer cell lines
was determined by measuring IC50 values using the SRB assay to de-
termine cell viability [32]. In all cases, cell survival values were nor-
malised against untreated controls.
Brieﬂy, 96 well-plates were seeded using 5000 cells per well; the
plates were left in the incubator at 310 K for 48 h in drug-free medium.
After this time, the lectins were added at multiple concentrations. The
stock solutions and the corresponding dilutions were prepared using
medium supplemented with only 1% of foetal calf serum to ensure that
no lectin deactivation occurred by non-selective protein binding [33].
The drug exposure time was 24 h. After this, the drug-containing
medium was removed by suction, cells were washed with PBS, and
lectin-free medium was added; cells were ﬁnally left to recover for 72 h
at 310 K. The sulforhodamine B colorimetric assay was used to de-
termine cell survival against an untreated control based on the mea-
surement of cellular protein content [32]. This assay relies on the
ability of the sulforhodamine B to bind electrostatically to basic amino
acid residues of proteins from ﬁxed cells. The sulforhodamine B ab-
sorbance at 570 nm was recorded on a BioRad iMark 96-well micro-
plate reader. The experiments were carried out as triplicates of dupli-
cates in independent experiments and their standard deviations were
calculated.
2.11. Cell cycle studies for A2780 cells
Cell cycle investigations were carried out by ﬂow cytometry using PI
staining. Brieﬂy, in a 6 well-plate 1.0 × 106 A2780 cells were seeded
and allowed to attach for 24 h at 310 K in a 5% CO2 humidiﬁed at-
mosphere. Following this, cells were treated with 2× IC50 concentra-
tions of DLasiL for 24 h. After drug exposure, the lectin was removed by
suction, cells were washed with PBS, harvested by trypsinization, wa-
shed twice with PBS, and centrifuged at 1000 g for 4 min. The cell
pellet was then resuspended in cold 70% ethanol and kept in a freezer
253 K for 24 h. Cells were centrifuged, the ethanol removed and cells
were washed with PBS, followed by staining with 500 μL of a mixture
containing PBS, 100 μL of PI stock solution and 160 μL of RNAse stock
solution. The sample was kept in the dark for 30 min, centrifuged and
the supernatant removed by suction. Cells were resuspended in fresh
PBS and were transferred to a ﬂow cytometry tubes to read the ﬂuor-
escence emission of PI bound to DNA at 617 nm. The data were ana-
lyzed using Flowjo software.
2.12. Induction of apoptosis in A2780 cells
Flow cytometry detection of induced apoptosis in A2780 ovarian
cancer cells was carried out using Annexin V-FITC and propidium
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iodide (PI) staining (BioVision Annexin V Apoptosis Detection Kit).
Brieﬂy, 1.0 × 106 cells were seeded on a 6-well plate in triplicate and
allowed to attach for 24 h in drug-free medium at 310 K. Cells were
then treated with DLasiL for a further 24 h using 2× IC50 concentra-
tions. These experiments used staurosporine (Sigma Aldrich, UK) as a
positive control. After the drug exposure period, the supernatant was
removed by suction, the cells washed with PBS, trypsinized, centrifuged
at 1000 ×g for 4 min, and the cell pellet further washed with PBS
twice. In order to stain the cells, the pellets were resuspended in 500 μL
of a mixture of PBS containing 10 μL of PI/sample and 5 μL of Annexin/
sample. Cells were incubated in the dark at ambient temperature for
30 min and then analyzed using a ﬂow cytometer Becton Dickinson
FACScan reading in Annexin V-FITC in the FL-1 green channel and PI in
the FL-2 red channel for ﬂuorescence detection.
2.13. Caspase 9 activity assay
Caspase 9 induction in A2780 cell lysates was determined by a
ﬂuorimetric assay (BioVision, UK) according to the manufacturer's in-
structions. The experiment included cells exposed to DLasiL at 2× IC50
concentration, as well as untreated negative controls and cells exposed
to staurosporine as positive control. After a 24 h incubation period,
cells were collected, trypsinized and lysed. The samples were split into
two tubes, one for protein quantiﬁcation using a Bradford assay and the
other to measure the caspase 9 activity. The assay was based on the
detection of the cleavage of substrate LEHD-AFC (AFC: 7-amino-4-tri-
ﬂuoromethyl coumarin). LEHD-AFC emits blue light (λmax = 400 nm);
upon cleavage of the substrate by caspase-9 or related caspases, free
AFC emits a yellow-green ﬂuorescence (λmax = 505 nm). All values,
determined as triplicates of triplicates, were normalised to protein
content and their standard deviations were calculated.
2.14. Confocal microscopy
A2780 ovarian carcinoma cells were seeded in 4-well microscopy
chambers (10,000 cells/well; 500 μl supplemented RPMI 1640
medium), left to attach for 24 h, and then treated for another 24 h with
diﬀerent concentrations of DLasiL (0, 0.5×, 1× and 2× IC50) that was
labelled using Alexa ﬂuor 647 (monoclonal antibody labelling kit from
Invitrogen; λex = 650 nm/λem = 665 nm). After treatment, medium
was removed, cells washed twice with PBS and ﬁxed with 4% paraf-
ormaldehyde solution (20 min at RT). Cell nuclei were stained using
DAPI (0.1 mg/ml; 10 min at RT; λex = 358 nm/λem = 461 nm) fol-
lowed by two washes with PBS. Cells were imaged using a Leica SP5
confocal microscope.
3. Results
We investigated the structural and physicochemical properties of
DLasiL using tandem mass spectrometry, EPR, ICP-MS, CD and ﬂuor-
escence emission spectroscopy, which, to the best of our knowledge,
comprises the ﬁrst detailed physical characterisation of the DLasiL
lectin. We have compared these data to other relevant lectins, ConBr,
ConM and DSclerL, and have explored their anticancer activity towards
several cancer cell lines. Additionally, we have investigated the me-
chanism of the antiproliferative activity of DLasiL lectin.
3.1. Structural investigations
We determined the amino acid sequence, metal content, tryptophan
accessibility/microenvironment and thermal stability of DLasiL lectin.
Tandem mass spectrometry analysis of sets of overlapping peptides
obtained by proteolytic digestions allowed 89% of the amino acid se-
quence of DLasiL to be determined (Supporting information Table S1).
This was conﬁrmed and completed by cloning and sequencing the lectin
gene. The protein sequence (Fig. 1) shows a high degree of identity with
other Diocleinae lectins. DLasiL is therefore likely to also form homo-
tetramer, with each of the 4 subunits (α-chain) containing 237 amino
acids distributed between two chains: β-chain (residues 1–118) and γ-
chain (residues 119–237; Supporting information, Table S1). Further-
more, the isotope-averaged molecular masses calculated for the full-
length α-chain (25,410 Da) and its derived β- (12,816 Da) and γ-
(12,611 Da) fragments are in excellent agreement with the reported
experimentally-determined mass [22].
Most lectins are metal-dependent proteins, often containing Mn(II)
and Ca(II) ions. We obtained the six-line EPR spectra typical of Mn(II)
in aqueous solutions of ConBr, ConM, DSclerL and DLasiL (0.4 mM),
thus conﬁrming the presence of paramagnetic Mn(II) in all four lectins
(Supporting Fig. S1). Additional ICP-MS measurements were used to
obtain quantitative information on Mn content and that of other EPR
silent metals (e.g. Mg, Ca). Mg, Mn and Ca were found in signiﬁcant
amounts in all four lectins (Supporting information Table S2). The
highest amount of Mn was found in DSclerL (ca. 3 Mn per subunit),
followed by ConBr and ConM (ca. 1 Mn per subunit), and DLasiL (lower
than 0.5 per subunit; Fig. 2, Table S2).
Fluorescence emission studies were carried out in order to obtain
information about the solvent accessibility of the tryptophan residues in
relation to conformational ﬂexibility in the DLasiL lectin. The stability
of the DLasiL lectin with respect to denaturation by guanidinium hy-
drochloride (Gdn-HCl) was investigated. DLasiL lectin exhibited a
maximum emission at 334 nm that is assigned mainly to the ﬂuorescent
tryptophan residues in the folded protein, upon excitation at 280 nm
(Supporting information Fig. S2), while the maximum emission was
red-shifted to 352 nm upon denaturation with Gdn-HCl. A more de-
tailed investigation of tryptophan accessibility and the polarity of its
microenvironment in both native and denatured DLasiL lectin was
carried out by using CsCl, KI and acrylamide as cationic, anionic and
neutral quenchers, respectively (Table S3, Figs. S3 and S4). DLasiL
experienced a strong ﬂuorescence suppression on interaction with ac-
rylamide (56%), followed by iodide (44%) and cesium (30%) as shown
by Stern-Volmer plots (see Supporting information Fig. S3). A similar
trend in ﬂuorescence quenching of denatured DLasiL lectin was ob-
served (Supporting information Fig. S4). The near-UV CD spectrum of
the native DLasiL lectin was recorded in buﬀered solution at 298 K
(Fig. 3). This spectrum exhibited two positive absorption bands at ca.
285 and 290 nm that arise from contributions of the side chains of
tryptophan and tyrosine residues. The thermostability of DLasiL lectin
in phosphate buﬀer was investigated in the near-UV region by mon-
itoring the CD signal at 290 nm in the temperature interval 303 to
363 K (Fig. 3A). A denaturation midpoint was observed at 345 K, in
agreement with a previous study in which the far-UV region was
monitored [22]. The CD spectra acquired in the near-UV region at
diﬀerent temperatures showed a similar pattern of stability compared
to that observed in the far-UV region and the variable-temperature
experiments at 290 nm (Supporting Fig. S5).
Fig. 3B shows the CD spectrum of native DLasiL in the near-UV
region overlaid with that in the presence of 100 mM glucose or 100 mM
mannose. There were no signiﬁcant changes in the near-UV CD spectra
of DLasiL upon addition of these sugars, suggesting that sugar binding
does not have a major eﬀect on the conformation of the lectin.
Some of the above observations may be rationalized by inspecting
the 3D structures of DLasiL and the other lectins that are included for
comparison. The structure of DLasiL (Figs. 4 and S6) was modelled on
that of Dioclea guianensis lectin (pdb 1H9W), which has 96% sequence
identity to DLasiL. The Ca/Mn site contains four ligands for Ca (E8,
H24, D10 and D19), while the latter two aspartates form bridges and
bind also to Mn. The latter is in addition bound to residue N14 and the
backbone carbonyl oxygen of Y12. This dinuclear site is adjacent to the
surface sugar-binding site (Fig. 4(A)).
Importantly, analysis of dimeric and tetrameric assemblies (Fig. S6,
based on the X-ray structure of ConBr; pdb 4H55) suggested that W88 is
less exposed to solvent when the lectin oligomerises, with implications
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for protein tryptophan ﬂuorescence discussed later. Moreover, other
weak Mn binding sites at the interface between monomers are observed
in the X-ray structure of D. guianensis lectin (pdb 1H9W) and might
explain the binding of> 1 Mn per subunit in DSclerL (weak sites). The
low Mn content in our DLasiL samples might weaken the oligomerisa-
tion and increase the monomer population, which is expected to aﬀect
Trp88 ﬂuorescence.
3.2. Biological studies
3.2.1. Cell viability assays
We determined the antiproliferative activity of lectins ConBr, ConM,
DLasiL and DSclerL towards a variety of human cancer cell lines of
breast, ovarian, lung and prostate origin, Table 1. In general, all lectins
showed potent anticancer activity towards the A2780, A549, and PC3
cell lines, with all IC50 values in the nanomolar range varying from 52
to 529 nM. There are no clear trends in the comparative potency of the
four lectins in the three cell lines tested. Nonetheless, it appears that the
highest activity is achieved in A2780 human ovarian cancer cells. IC50
values determined as ranges with 95% conﬁdence intervals are in the
Supplementary Information, Table S4. Particularly, DLasiL exhibited
the lowest IC50 value of 52 ± 2 nM. We also tested DLasiL towards the
MCF7 breast cancer cell line and determined its IC50 value to be
275 nM.
3.2.2. Cell cycle analysis
In the antiproliferative activity experiments carried out (vide
supra), DLasiL exhibited the highest potency towards A2780 ovarian
cancer cells, hence we investigated the cellular behaviour of the lectin
in this cell line. In particular, we used ﬂow cytometry to investigate the
eﬀect of the lectin on the cell cycle of the ovarian cancer cells (Fig. 5).
Flow cytometry analysis of negative untreated controls of A2780
ovarian cancer cells were carried out. As expected, most of the cell
population of the corresponding FL-2 histogram is located in the G1
phase (71 ± 1%) while percentage of cells in the S and G2/M phases
are 19.1 ± 0.5% and 9 ± 1%, respectively. As a positive control, we
determined the percentages of cell population in samples treated with
the clinical anticancer drug cisplatin (CDDP). In this case, we observed
Fig. 1. CLUSTAL 2.1 multiple sequence align-
ment for lectins DLasiL, DGuiaL, DSclerL,
DGranL, ConBr, and ConM. Residues involved in
the canonical binuclear Ca/Mn site are high-
lighted in grey: E8, H24, D10 and D19 bind Mn,
D10 and D19 also bridge to Ca, which is also
bound by N14 and by the backbone oxygen of
Y12. Residues involved in carbohydrate binding
are shown in orange, and tryptophan residues are
highlighted in green. Highlighted in yellow are
loop residues 117–122, and residue 131. The loop
is disordered in some lectin structures (e.g.
DGuiaL, pdb 1H9W, template for homology
modelling), and it is thought that the nature of
residue 131 plays a role in ordering this loop. An
ordered loop indicates a more stabilised inter-
face. The location of the loop is quite close to
Trp88 (W88); its ﬂexibility may also directly af-
fect W88 solvent exposure. Residues K138 and
D139 (cyan) from the second monomer come into
the vicinity of W88 upon dimerisation. (For in-
terpretation of the references to color in this
ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 2. Stoichiometric ratio for the most abundant metals per
lectin protein subunit as determined by ICP-MS.
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a sharp increase in the S phase population up to 50 ± 3% while the G1
phase is reduced to 16.1 ± 0.8%. Population in the G2/M phase ac-
counted for 33 ± 9%. The observed S phase arrest caused by cisplatin
is a well-established eﬀect of this platinum drug. It is a result of a
mechanism of action that involves covalent binding and the subsequent
structural modiﬁcation of the DNA double helix.
In comparison, A2780 cells treated with 2× IC50 equipotent con-
centrations of DLasiL for 24 h showed a signiﬁcant reduction of the G1
phase population to 57.1 ± 0.3%. This is a result of an increase in the
G2/M phase (to 22.0 ± 0.6%) with p = 0.001. Meanwhile, changes in
the S phase (up to 20.8 ± 0.6%) are minor, but still statistically re-
levant (p = 0.024).
3.2.3. Induction of apoptosis in A2780 cells
According to the cell cycle analysis, in which lectin DLasiL induces a
G2/M arrest in the ovarian cancer cells upon 24 h exposure to 2× IC50
concentrations, and given that lectins with similar behaviours exert
their antiproliferative activity by inducing apoptosis, we decided to
investigate the induction of this programmed cell death in A2780 cells.
The labelling of cells with Annexin V-FITC/PI (propidium iodide)
generates the ﬂuorescence patterns detected by ﬂow cytometry for four
distinct cell populations shown in Fig. 6. A bidimensional dot plot can
then be divided into four quadrants coded as Q1, Q2, Q3 and Q4. Q1 is
associated with non-viable cells, which have lost membrane integrity
and are located in the upper left quadrant. They show low ﬂuorescence
for annexin V-FITC but a high reading in the FL-2 red channel corre-
sponding to PI. Q2 is associated to late apoptotic cells located in the
upper right quadrant, positively labelled by annexin V-FITC and PI.
These cells have lost the symmetry of the phosphatidylserine membrane
and have further lost membrane integrity. Q3 represents early apoptotic
cells found in the lower right quadrant, which show high annexin V
FITC ﬂuorescence in the FL-1 green channel but no detectable PI signal
in the FL-2 red channel. Q4 is constituted by a group of viable cells that
Fig. 3. Circular dichroism spectroscopy of DLasiL in 10 mM phosphate buﬀered saline at
298 K in the near-UV region. A) Thermal unfolding of DLasiL monitored at 290 nm from
303 to 363 K. B) Eﬀect of the addition of binding sugars at 298 K: native DLasiL (blue
solid line), DLasiL +100 mM glucose (red dashed line) and DLasiL +100 mM mannose
(green dashed line). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 4. A) Monomeric homology model of DLasiL, based on
the X-ray structure of D. guianensis seed lectin (DGuiaL; pdb
1H9W, 96% identity). The backbone is shown in grey,
tryptophan residues in green, sugar-binding residues in
orange, and atom-colored (CPK) sticks for residues involved
in metal binding. B) Closeup of canonical binuclear Mn/Ca
site in leguminous seed lectins as predicted for DLasiL,
using DGuiaL (pdb 1H9W) as example. Mn is shown in
magenta, and Ca in blue. Coordinating water molecules are
not shown. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version
of this article.)
Table 1
Antiproliferative activity of lectins ConBr, ConM, DLasiL and DSclerL against human
A2780 ovarian, A549 lung, MCF-7 breast and PC3 prostate cancer cells. The experiments
included 24 h of drug exposure and 72 h of recovery time in drug-free medium. All values
were determined as duplicates of triplicates in independent experiments and their stan-
dard deviations were determined.
Lectin IC50 (nM)
A2780 A549 MCF-7 PC3
ConBr 108 ± 14 95 ± 14 1146 ± 24 529 ± 8
ConM 67 ± 2 62 ± 4 1382 ± 17 176 ± 2
DLasiL 52 ± 2 224 ± 10 275 ± 4 167 ± 1
DSclerL 64 ± 4 102 ± 8 1250 ± 9 264 ± 1
Fig. 5. Flow cytometry analysis of A2780 ovarian cancer cells exposed to 2× IC50 con-
centrations of DLasiL or cisplatin. The bar chart represents the percentage of cell popu-
lation in each of the cell cycle phases, G1, S and G2/M determined after propidium iodide
staining. The experiments included 24 h of drug exposure and no recovery time in drug-
free medium. Statistical signiﬁcance was evaluated using a Welsh test against untreated
negative controls (* p < 0.05, ** p < 0.01). Values are expressed as means and stan-
dard deviation of two independent experiments performed in duplicate.
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are located in the lower left quadrant and have not been labelled by
annexin nor propidium iodide. As expected, untreated cells were mostly
viable (92 ± 2%), with small populations of early and late apoptotic
and non-viable cells (4.3 ± 0.2, 1.8 ± 0.4 and 2.8 ± 0.6, respec-
tively). Treatment of A2780 cells with DLasiL led to a small increase in
the population of non-viable cells, but the populations of early and late
apoptotic remained unchanged.
3.2.4. Caspase 9 activity
To conﬁrm that the mechanism of action of lectin DLasiL involves
the activation of apoptosis, we investigated whether increased levels of
the apoptotic initiator caspase 9 were observed after exposure to the
lectin, Fig. 7. A2780 ovarian cancer cells were treated with DLasiL (2×
IC50 concentration) or with staurosporine (as a positive control, well-
known to induce apoptosis), and the levels of caspase 9 were measured
by the ﬂuorescence detection of the cleavage of substrate LEHD-AFC
(AFC: 7-amino-4-triﬂuoromethyl coumarin). A 45% increase in the
level of caspase 9 produced by 24 h exposure to lectin DLasiL compared
to the negative controls was observed (Fig. 7).
3.2.5. Confocal microscopy
The cellular distribution of DLasiL lectin was explored using con-
focal microscopy. Imaging of A2780 carcinoma cells treated with dif-
ferent concentrations (0–2× IC50) of ﬂuorescent Alexa ﬂuor 647-la-
belled DLasiL showed that the protein accumulated in cells in a
concentration-dependent manner (Fig. 8, stacks A–D). The protein is
distributed around the periphery of the nuclei (stained using DAPI). No
colocalisation between the ﬂuorescent protein and DAPI was observed
(even at the highest concentration used, 2× IC50; Fig. 8; stacks A–D;
Figs. S7–S10; Videos S1–S4). Additionally, high concentrations of the
lectin led to morphological changes in treated cells. A2780 cells treated
with 2× IC50 of DLasiL were more widely spread and had enlarged
nuclei when compared with untreated cells or cells treated with low
concentrations of the protein.
4. Discussion
Although lectins puriﬁed from various Diocleinae subtribe seeds
show only minor diﬀerences in their amino acid sequences, their bio-
logical activities can diﬀer signiﬁcantly [14]. These diﬀerences in ac-
tivities are mostly due to the relative positions of the carbohydrate
binding sites, and the dimer to tetramer balance, which is pH-depen-
dent. For example, substitution of only two amino acid (D58 and A70)
associated with the carbohydrate binding site is responsible for a more
opened binding site in the Canavalia brasiliensis lectin (ConBr) com-
pared with the Canavalia ensiformis lectin (ConA) [14,34]. We de-
termined the amino acid sequence of DLasiL and compared it through
sequence alignment with other Diocleinae lectins previously char-
acterized (Fig. 1). This showed a high degree of sequence similarity
between the four lectins isolated and analyzed in this work (ConBr,
ConM, DSclerL and DLasiL), with the DLasiL and DSclerL amino acid
sequences diﬀering only in 12 residues (Fig. 1). However, the moderate
change in amino acid composition still promoted signiﬁcant diﬀerences
in chemical properties (e.g. metal contents and ﬂuorescence) and bio-
logical activity.
Plant lectins require divalent metals (Ca(II) and Mn(II) ions or
others e.g. Mg(II)) for their function. Their role seems to be essentially
structural, especially for creating the sugar-binding sites [35–37].
DLasiL lectin contained the lowest levels of these metal ions (Fig. 2 and
Table S2; see details in Supporting information), which, given the
complete conservation of metal-binding residues (Figs. 1 and 3(B)) and
the uniform protocol for protein puriﬁcation, could be due to diﬀer-
ences in plant growth or soil conditions, or to subtle diﬀerences in in-
herent chemical properties due to the small diﬀerences in primary se-
quence. The Mn contents of DSclerL were surprisingly high, but it is
noted that the X-ray structure of DGuiaL (pdb 1H9W) shows several
weak Mn sites at the interface between monomers. Most notably, H180
(a neighbor of W88; see below) is bound to a Mn ion, with two ordered
water molecules, one of which forms an H-bond to a backbone nitrogen
in the adjacent monomer (Fig. S6). Thus, in terms of both structural
stability of individual monomers, and of stability of the tetramer, it is
conceivable that metal contents and structural stability are correlated –
in turn, the lower the metal content, the more ﬂexible and dynamic the
protein will behave. It is likely that such diﬀerences in dynamic prop-
erties play important roles in the biological activity of lectins. It may be
noted that the medium used for all biological assays with DLasiL was
supplemented with Mn(II), Ca(II) and Mg(II) in an attempt to ensure
that all metal binding sites on the protein were saturated.
Fluorescence studies showed that DLasiL lectin exhibited a max-
imum emission at 334 nm when excited at 280 nm, which suggests a
more polar environment for tryptophan residues compared to other
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Fig. 6. Flow cytometry analysis of A2780 ovarian cancer cells exposed to DLasiL using
ﬂuorescence labelling with annexin V-FITC and propidium iodide. A) Dot plot of negative
controls and 24 h lectin-exposed cells B) Bar chart of the percentages of cell population in
each of the quadrants of the ﬂow cytometry dot plots (Q1: non-viable, Q2: late apoptotic,
Q3: early apoptotic and Q4: viable cells). Statistical signiﬁcance against the negative
untreated control was evaluated using Welch's test with * p < 0.05, ** p < 0.01, ***
p < 0.001. Values were determined as the means for triplicate experiments and their
standard deviations were calculated.
Fig. 7. Caspase 9 activation in A2780 ovarian cancer cells. Cells were treated with DLasiL
(2× IC50 concentration), staurosporine as a positive control, or were untreated as ne-
gative controls. Statistical signiﬁcance was evaluated using a Welsh test against the un-
treated controls (* p < 0.05). Values are expressed as means and standard deviation of
triplicates.
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lectins [27]. All four DLasiL tryptophan residues are fully conserved in
all lectins under study here, as well as in DGuiaL. This is also true for
their immediate environments [29,38]. Inspection of these environ-
ments reveals that W40 and W109 are fairly buried and surrounded by
largely hydrophobic residues (W40: L9, I25, M42, V65, Y67 and F197;
W109: V91, L93, F111, F128, F130, F133, V140 and F212), that W182
is fairly solvent-exposed, with only the polar N82, S185 and the small
A186 as neighbors, and that the environment of W88 is also quite polar:
It forms a stacking interaction with H180 from the same monomer, and
in the dimer or tetrameric forms only, K138 and D139 from a second
monomer enter its vicinity. Thus, in a multimeric state, W88 is clearly
more buried than in the monomer. Furthermore, W40 is close to the
dinuclear metal binding site (ca. 10 Å), so its accessibility may be af-
fected by the protein's metalation state. We suggest that the more polar
tryptophan environment observed for DLasiL may be an indication for
higher structural ﬂexibility and/or a lower degree of tetramerisation –
which would also be in keeping with the lower metal contents of our
preparation that may lead to decreased conformational stability and
oligomerisation.
More detailed measurements carried out using CsCl, KI and acry-
lamide as ﬂuorescence quenchers showed that acrylamide is the most
eﬀective suppressor of the native DLasiL ﬂuorescence, followed by io-
dide (Table S3, Fig. S3), while Cs(I) quenched less eﬃciently. These
results might indicate that the neutral acrylamide and anionic I−
quenchers have more access to the tryptophan residues than the ca-
tionic quencher Cs(I). It may be suggested that the three diﬀerent
ﬂuorescence quenchers target diﬀerent tryptophans to diﬀerent de-
grees. Access by Cs(I) may be largely conﬁned to W182, as the micro-
environments of W40 and W109 are probably too hydrophobic, and
access to W88 may be, at least in the dimer/tetramer, partially re-
stricted due to the presence of both K138 and potentially a weakly
bound Mn ion. The residue W88 could be further explored as an in-
teresting probe for monomer-dimer equilibrium studies.
The maximum emission wavelength shifted to 352 nm upon dena-
turation with guanidinium hydrochloride (Gdn-HCl), which is typical of
tryptophan residues fully exposed to water as consequence of protein
unfolding. As expected, the extent of ﬂuorescence quenching was
higher for denatured DLasiL (Table S3, Fig. S4), since the accessibility
of the quenchers to the tryptophan residues is increased in the unfolded
lectin. The results obtained with the denatured lectin were also con-
sistent with a neutral and positively accessible tryptophan micro-
environment, as shown by the Stern-Volmer analysis (Table S3 and Figs.
S3 and S4).
The circular dichroism (CD) spectra of proteins depend on their
secondary structure and conformation. Therefore, this technique pro-
vides structural information on proteins, and can be used to study
conformational changes due to binding of ligands, temperature, dena-
turants, mutations, etc. We have reported previously the relative β-
sheet and α-helical content of native DLasiL (40.2% antiparallel β-
sheet, 4.6% parallel β-sheet, 7.2% α-helices, 17.3% turns, and 28.7%
unordered structure), and studied its thermal stability in the far-UV
range by using CD spectroscopy [22]. The high thermal stability ob-
served for DLasiL is a common feature of legume lectins in general [39],
and makes them attractive proteins for biotechnological purposes.
So far, a few lectins have shown anticancer activity in vitro and in
vivo, and are reported to bind to cell membranes of cancer cells or to
their receptors, causing cytotoxicity, apoptosis and inhibition of tumour
growth [7]. The binding aﬃnity of lectins for various glycans and
glycoproteins on the cell wall is well described elsewhere [40]. Ligand
binding can aﬀect the tertiary structure of a protein. Therefore, we
employed CD spectroscopy to study the binding of diﬀerent carbohy-
drates to DLasiL lectin. Two positive absorption bands with maximum
Fig. 8. Z projection of confocal images of A2780 ovarian
carcinoma cells treated for 24 h with: A) negative control;
B) 0.5× IC50 DLasiL; C) 1× IC50 DLasiL; D) 2× IC50
DLasiL. DLasiL was labelled with Alexa ﬂuor 647 (red);
nuclei stained with DAPI (blue). (For interpretation of the
references to color in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
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wavelengths at ca. 290 nm and 285 nm were observed. These bands
arise from contributions of the side chains of tyrosine and tryptophan
residues. We observed only minor changes in the near-UV CD spectrum
of DLasiL on incubation with glucose or mannose under the experi-
mental conditions employed (Fig. 3B). This result showed that the
binding of these carbohydrates has little eﬀect on the tertiary structure
of native DLasiL. This is expected since the divalent metals binding
organize the sugar binding site, which is not further altered.
Interestingly, DLasiL showed the highest antiproliferative activity
towards A2780 cells of the lectins tested (IC50 52 ± 2 nM), followed
by DSclerL (IC50 64 ± 4 nM), ConM (IC50 67 ± 2 nM) and ConBr
(IC50 108 ± 14 nM) (Table 1). DLasiL and DSclerL exhibited higher
activity in the A2780 ovarian cell line than in A549 lung, or PC3
prostate cells, with IC50 values in the range of 100–275 nM in the latter.
The other lectins tested showed a similar behaviour, and the potency of
ConBr is 5-fold lower in the PC3 cells when compared to A2780 and
A549 cells (IC50 values 529 ± 8, 108 ± 14 and 95 ± 14 nM, re-
spectively). Lectin binding aﬃnity to various glycans and glycoproteins
varies in diﬀerent tumours, because of the distinct carbohydrates
moieties on their surface [33,40]. Therefore, these changes observed in
the antiproliferative activity might suggest the diﬀerential recognition
of glycan-structures contained within the diﬀerent cell lines studied.
According to Packer et al., ovarian cancer cells show moieties with high
mannose content as the most abundant structures amongst other N-
glycans subgroups [41]. Plant lectins including those studied here, are
thought to be glucose/mannose selective binders, which supports this
hypothesis.
More detailed cellular studies were conducted with DLasiL invol-
ving cell cycle and apoptosis studies. The mammalian cell cycle is well
studied by measuring changes in the cellular DNA content through
transitions in diﬀerent cellular growth phases, such as G1, S and G2/M.
Cellular DNA content can easily be measured by detecting propidium
iodide (PI) ﬂuorescence, as this organic dye intercalates quantitatively
into DNA. The FL-2 ﬂow cytometry histograms show 3 sections, 2 major
peaks corresponding to G1 and G2/M stages with one and two copies of
DNA correspondingly, and a third section bridging the two previous
ones which represents cells in S phase with the cell population under-
going duplication of DNA [42,43]. Contrary to cisplatin, in the case of
the lectin DLasiL, there is a clear arrest in G2/M phase. This eﬀect on
the cell cycle of cancer cells has been previously reported, for instance a
series of lectins extracted from mushrooms can induce G2/M arrest of
human leukaemia U937 cells in consequence initiate an apoptotic
cascade. In this case, the cell cycle arrest may be related to the upre-
gulation of p21/Waf1 and a subsequent decrease in Bcl-2 before cyto-
chrome c release into the cytosol and caspase-9 activation [44,45]. In a
similar way, an N-acetyl-D-glucosamine lectin from Psathyrella asper-
ospora is known to cause G2/M cell cycle arrest in HT29 cells by
binding to GlcNAc-terminated glycans after 24 h of drug exposure.
Lectins can induce death in cancer cells via diﬀerent apoptotic
pathways [46]. Caspase-9 initiates the intrinsic apoptosis pathway,
associated with changes in morphological and biochemical character-
istics [47], activating a process that involves other types of caspases
such as procaspase-3 and caspase-3 [48].
Apoptosis is often suggested as the mechanism by which plant lec-
tins can induce cell death [46]. Based on several reports, ConA exerts its
antiproliferative activity through apoptotic mechanisms which involve
binding to glycoproteins of cell membranes. Once it is internalized, it
locates preferentially in the mitochondria where it activates a number
of signalling pathways [14]. This lectin exhibits high anti-proliferative
activity in A375 melanoma cells. In this particular case, its mechanism
of action relies on the activation of an apoptotic cascade involving
caspase-9 and caspase-3, causing mitochondrial collapse and leading to
release of cytochrome c into the cytosol [47]. ConA also adheres to
Merkel cell skin carcinoma [48], and may also induce mitochondrial
apoptosis, BNIP3-mediated mitochondrial autophagy, and eventually
causes death of tumour cells [6].
Regarding the investigations of apoptosis induction, we analyzed
four distinct populations in A2780 cells exposed to lectin DLasiL under
similar conditions to those used in the cell cycle experiments (24 h drug
exposure at 2× IC50 concentrations, no recovery time) and compared
them to those of untreated controls. As expected, negative controls
exhibit most of their cell population in the Q4 quadrant in which viable
cells have low ﬂuorescence in both FL-1 green and FL-2 red channels
(92 ± 2%). Populations in quadrants Q1, Q2 and Q3 are relatively low
and in no case above 5% (Q1: 4.3 ± 0.2, Q2: 1.8 ± 0.4 and Q3:
2.8 ± 0.6). Cells exposed to lectin DLasiL also had most of the popu-
lation (88 ± 2%). in Q4 while Quadrants Q2 and Q3, which exhibit
high Annexin V ﬂuorescence in the FL-1 green channel, remained un-
changed with percentages of cell populations of 1.9 ± 0.6 and
2.8 ± 0.7% respectively. Surprisingly, the only statistically relevant
change observed (p = 0.035) is an increase of the population in Q1
with only high ﬂuorescence in the FL-2 red channel caused by PI in-
tercalation into DNA after the membrane of the cells has been com-
promised. These results and in particular changes in the Q1 quadrant do
not indicate that there is induction of apoptosis in the ﬁrst 24 h of drug
exposure. In contrast, when we investigated the activation of caspase 9 -
we observed a 45% increase in ﬂuorescence from the cleavage of sub-
strate LEHD-AFC (AFC: 7-amino-4-triﬂuoromethyl coumarin) (Fig. 7)
which suggests an early activation of an apoptotic cell death. Such is the
case of caspase-activated cell death by ConA, another lectin which
belongs to the same Diocleinae subtribe [47]. Taken together, these
contrasting results open up several possibilities, including the fol-
lowing. First that the activation of the apoptotic cascade does occur
within the 24 h of drug exposure, and it is not until the 72 h of cell
recovery time in drug-free medium that the cell viability is aﬀected.
Hence changes in the phospholipid membrane are not detected under
the conditions of our apoptosis experiment. Second, that a diﬀerent
mechanism of cell death could be involved in the antiproliferative ac-
tivity of DLasiL. The latter is possible as it is recognised that not all
caspase activations necessarily lead to apoptotic cell death [49,50]. An
example is caspase-3 activation in PHA-stimulated T lymphocytes in the
absence of apoptosis [50].
Additionally, confocal microscopy data suggested that DLasiL is
localised in the membrane or cytosol of treated cells. Plant lectins are
known to attach to the cellular membrane of treated cells and then
become internalized, being able to localise in diﬀerent cellular com-
partments. For example, ConA targets mitochondria in mice hepatoma
cells [51], while WGA is found in lysosomes and trans‑Golgi network in
human prostate cancer cells [52]. Other lectins such as frutalin, XCL or
AAL [53–55] are reported to accumulate around the nuclei of cells, as
DLasiL does. Interestingly, frutalin possesses some antiproliferative
activity in HeLa cells, and is also capable of altering the cellular mor-
phology and induce apoptosis [53]. However, while frutalin is also
found in the nucleus of treated cells, DLasiL is not, indicating diﬀer-
ences in their cellular behaviour and, probably, mode of action. Further
experiments are required to fully understand the cellular distribution
and speciﬁc targets of DLasiL leading to the potent antiproliferative
activity observed.
5. Conclusions
We report studies of the recently isolated seed lectin DLasiL.
Sequence comparisons and homology modelling suggested that its
structure is similar to that of related lectins, in particular the con-
servation of the dinuclear Ca/Mn, sugar- and additional metal binding
sites at monomer interfaces. DLasiL lectin showed potent nanomolar
activity towards human cancer cell lines, as good or better than the
activity of other lectins from the Diocleinae subtribe. Particularly high
potency was observed against A2780 human ovarian cancer cells (IC50
52 ± 2 nM). This suggests high aﬃnity of DLasiL towards the glycans,
glycoproteins and/or receptors present in the cytosol and/or cell sur-
face of A2780 cells.
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Investigations into the cellular basis of the antiproliferative activity
of lectin DLasiL showed G2/M cell cycle arrest in A2780 ovarian cancer
cells after 24 h exposure, as previously reported for related lectins.
Further ﬂow cytometry studies did not show a signiﬁcant increase in
the apoptotic populations within this time frame, but caspase 9 acti-
vation was detected, suggesting that DLasiL causes a delayed onset of
programmed cell death. Additionally, confocal microscopy studies
showed that ﬂuorescently-labelled DLasiL lectin is taken up by A2780
cells in a concentration-dependent manner over the range 0.5–2× IC50,
and is localised around the periphery of the nucleus (but not in the
nucleus), perhaps in the cytoplasm and at glycosylation sites in the
endoplasmic reticulum. DLasiL treatment caused a marked change in
cell morphology, enlarging the nuclei and spreading the cells.
This is the ﬁrst report of the antiproliferative activity of newly
isolated lectins DLasiL and DSclerL. These natural products can be
readily isolated and puriﬁed from natural sources or produced as re-
combinant proteins with potential for high speciﬁcity. Additionally,
lectins might be useful auxiliary agents for the reduction of side eﬀects
associated with current chemotherapy and radiotherapy. Lectins are
resistant to digestion, survive through the gut, bind to gastrointestinal
cells entering in the circulation, and maintain their biological activity
[56]. For example, lectins from mistletoe provide an alternative therapy
for breast cancer showing a relevant clinical eﬀect in tumour progres-
sion throughout survival and recurrences [57]. Overall, the current
investigation has led to the discovery of highly potent plant lectins,
which might prove to be valuable for cancer treatment in the future.
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